Loading...
•
Jun 30, 2022
United Therapeutics Q2 2022 Earnings Report
United Therapeutics' financial performance saw revenue growth, driven by Tyvaso sales, while net income decreased due to increased expenses and other factors.
Key Takeaways
United Therapeutics reported a 5% year-over-year increase in total revenues for Q2 2022, reaching $466.9 million. This growth was primarily driven by increased sales of Tyvaso. However, net income decreased by 33% to $116.0 million compared to the same period in the previous year, impacted by increased operating expenses and other expenses.
Total revenues increased by 5% year-over-year to $466.9 million.
Net income decreased by 33% year-over-year to $116.0 million.
Tyvaso sales increased by 31% year-over-year, driven by an increase in quantities sold after label expansion.
The company launched Tyvaso DPI after FDA approval and saw first commercial shipments in June 2022.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
The company is focused on expanding the use of Tyvaso and advancing its pipeline programs, including studies for Tyvaso in IPF and PH-COPD, and ralinepag in PAH. They aim to reach 6,000 patients on Tyvaso by the end of 2022.
Positive Outlook
- FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD.
- Centers for Medicare and Medicaid Services updated its Local Coverage Determination (LCD) for Tyvaso to include an indication for PH-ILD, effective June 5, 2022.
- Enrollment is ongoing for the phase 3 PERFECT study evaluating Tyvaso for the treatment of WHO Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
- The company is enrolling two phase 3 studies to support the potential approval of oral ralinepag for PAH.
- Tyvaso may offer a treatment option for patients with fibrotic lung disease, supported by data from the INCREASE study.
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results.
- The decrease in Unituxin revenues resulted primarily from a decrease in quantities sold.
- The decrease in Adcirca revenues resulted primarily from higher gross-to-net deductions and, to a lesser extent, a decline in bottles sold as a result of generic competition for Adcirca.
- Increased spending on preclinical work on technologies designed to increase the supply of transplantable organs.
- The company assumes no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
Revenue & Expenses
Visualization of income flow from segment revenue to net income